News & Events – Pappas Capital

Most Recent 2019 2018 2017 2016 2015 2014 2013 2012

05.19.2020

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financin...

05.19.2020

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, ...

05.01.2020

HealthpointCapital Acquires Majority Stake in IlluminOss Medical,...

04.02.2020

Curzion Pharmaceuticals Acquired by Horizon Therapeutics

01.27.2020

Liquidia Submits New Drug Application for LIQ861 (treprostinil) i...

12.16.2019

Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with F...

10.23.2019

Allievex Completes Series A Financing Led by Pappas Capital and N...

10.11.2019

Former CoLucid Drug, Lasmiditan, Receives FDA Approval

09.30.2019

Vertex and Ribometrix Establish Strategic Collaboration to Discov...

09.27.2019

Ribometrix Announces $7.8 Million in New Funding to Advance RNA-T...

09.16.2019

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Vir...

09.16.2019

Amplyx Pharmaceuticals Announces Positive Preliminary Data from O...

09.11.2019

Alex Arfaei Joins Pappas Capital As Partner

09.09.2019

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for Fosman...

07.17.2019

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

07.16.2019

The Wall Street Journal Reports on Expansion of Leadership Team a...

07.16.2019

Pappas Capital Expands Leadership Team With Appointments Of Kyle ...

05.20.2019

Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics ...

05.09.2019

Milestone Pharmaceuticals Announces Pricing of Upsized Initial Pu...

02.28.2019

IlluminOss Medical Launches the IlluminOss® Bone Stabilization Sy...

01.07.2019

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data...

11.13.2018

Ribometrix Announces $30 Million Series A Funding to Advance Pipe...

11.07.2018

Mirum Pharmaceuticals Secures $120 Million in Series A Financing

10.25.2018

Milestone Pharmaceuticals Announces $80 Million Private Financing

10.17.2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing

10.01.2018

VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Cl...

09.05.2018

4D Molecular Therapeutics Raises $90 Million Series B Financing

08.08.2018

Milestone Pharmaceuticals Announces First Patient Randomized in t...

07.25.2018

Liquidia Technologies Announces Pricing of Initial Public Offering

06.20.2018

Kezar Life Sciences Announces Pricing of Initial Public Offering

04.25.2018

FDA Grants Fast Track Designation for OrphoMed’s ORP-101 fo...

04.10.2018

Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner

03.19.2018

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectiou...

01.10.2018

IlluminOss Medical Granted FDA Marketing Clearance for the Illumi...

01.03.2018

Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients w...

12.06.2017

Pappas Capital Portfolio Company Rotation Medical Acquired by Smi...

12.06.2017

Smith & Nephew Completes Acquisition of Rotation Medical Inc.

10.23.2017

Smith & Nephew Acquires Tissue Regeneration Technology for S...

08.02.2017

Amplyx Pharmaceuticals Raises $67 Million in Series C Financing

08.01.2017

Milestone Pharmaceuticals Closes $55 Million Series C Financing

07.25.2017

Kezar Life Sciences Announces Successful Completion of Phase 1a S...

05.25.2017

Liquidia Technologies Announces Positive Phase 1 Data for LIQ865,...

05.24.2017

New Pappas Capital Fund Makes First Investment

05.24.2017

OrphoMed Secures $39 Million Series A Financing Round

05.11.2017

Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Pr...

03.27.2017

TESARO Announces U.S. FDA Approval of ZEJULA™ (niraparib) ...

03.07.2017

Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliv...

03.01.2017

Lilly Completes Acquisition of CoLucid Pharmaceuticals

02.03.2017

Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phas...

01.18.2017

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To...

10.17.2016

Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data...

09.28.2016

Athersys Receives FDA Agreement Under Special Protocol Assessment...

09.06.2016

CoLucid Pharmaceuticals Announces Achievement of Both Primary and...

08.18.2016

Rotation Medical Secures $12 Million in Series B Extension Financing

07.18.2016

IlluminOss Medical Completes Enrollment for U.S. Clinical Trial U...

07.06.2016

Syndax Expands Pipeline With Exclusive Worldwide License Agreemen...

06.10.2016

Merck to Acquire Afferent Pharmaceuticals

06.07.2016

CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMU...

05.19.2016

CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pi...

05.04.2016

Envisia Therapeutics Announces Positive Three-Month Interim Resul...

04.26.2016

Afferent Pharmaceuticals Announces Presentations of Chronic Cough...

03.23.2016

Envisia Therapeutics Secures $16.5 Million In Additional Series A...

03.02.2016

Syndax Announces Pricing of Initial Public Offering

03.01.2016

CoLucid Pharmaceuticals Announces Special Protocol Agreement for ...

02.29.2016

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Rang...

02.23.2016

CoLucid Pharmaceuticals Announces Confirmatory Support for Non-va...

02.17.2016

One-Year Results From Phase 2 Stroke Study of MultiStem® Cell The...

01.13.2016

Envisia Therapeutics Announces First Patient Dosed in Second Coho...

01.08.2016

Healios and Athersys Enter Into Regenerative Medicine Partnership...

01.05.2016

Afferent Pharmaceuticals named one of “The Hottest Startups...

01.04.2016

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collab...

12.08.2015

Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phas...

12.01.2015

Syndax Announces Initiation Of Entinostat Clinical Program In Jap...

11.30.2015

CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update

11.19.2015

Afferent Pharmaceuticals Expands Executive Leadership Team With A...

11.11.2015

Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF...

11.10.2015

Thrasos Strengthens Composition of Matter Coverage on THR-184 wit...

10.27.2015

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D....

10.09.2015

ENVISIA THERAPEUTICS’ LEAD PRODUCT CANDIDATE, ENV515 (travoprost ...

10.09.2015

Chimerix Presents Preliminary Data on Brincidofovir in Liver Tran...

10.09.2015

CoLucid Pharmaceuticals Announces Initiation of Phase 3 Long-Term...

10.09.2015

Medtronic TYRX(TM) Neuro Absorbable Antibacterial Envelope now Av...

10.08.2015

Wake Forest Baptist Medical Center Creates $15 Million Program to...

10.02.2015

Anthera Announces Initiation of the SOLUTION Clinical Study of Or...

09.30.2015

Liquidia Technologies and GlaxoSmithKline Advance Existing Collab...

09.28.2015

Afferent Pharmaceuticals Announces Positive Results in Phase 2b C...

09.17.2015

CardioDx Expands Patient Access to the Corus(R) CAD Test Through ...

09.02.2015

TESARO Announces U.S. FDA Approval of VARUBI™ (rolapitant)...

09.02.2015

Chimerix and BARDA Announce Continued Partnership in the Developm...

08.26.2015

SYNDAX ENTERS CLINICAL TRIAL COLLABORATION IN CANCER IMMUNOTHERAP...

08.24.2015

SYNDAX RAISES $80 MILLION IN SERIES C FINANCING

08.18.2015

Rotation Medical Featured in Local News Story

07.21.2015

IlluminOss Medical Appoints Clive Ridgwell as Vice President of S...

07.14.2015

Liquidia Technologies Names Robert A. Lippe Chief Operations Officer

07.08.2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study fo...

07.08.2015

Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Cro...

06.15.2015

Milestone Pharmaceuticals Closes US$17 Million Series B Financing...

05.06.2015

CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering

05.04.2015

Envisia Therapeutics to Present at ARVO 2015 Annual Meeting

04.29.2015

IlluminOss Medical Appoints Amy Orlick Berman as Vice President o...

04.28.2015

CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Piv...

04.14.2015

Envisia Therapeutics Names Dr. Rhett Schiffman Chief Medical Officer

03.31.2015

Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 ...

03.31.2015

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluati...

03.24.2015

IlluminOss Medical Announces the Enrollment of First Patient in P...

03.19.2015

A drug that could raise IQ – Balance Therapeutics raises $1...

03.19.2015

Anthera Announces $3 Million Research Award from Cystic Fibrosis ...

03.16.2015

Anthera Pharmaceuticals Announces Completion of Interim Analysis ...

03.03.2015

IlluminOss Medical Announces the Enrollment of First Patient in E...

03.02.2015

Athersys and Chugai Enter License Agreement and Collaboration to ...

02.08.2015

Triangle Global Health Consortium Recognizes Chimerix with 2015 C...

01.27.2015

Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515...

01.22.2015

Athersys and Cell Therapy Catapult Announce Grant to Support Clin...

01.13.2015

CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C P...

01.12.2015

Chimerix Receives Notice of Allowance for Brincidofovir Compositi...

01.12.2015

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phas...

01.07.2015

Ultragenyx Announces License of Intellectual Property Related to ...

01.07.2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocet...

01.07.2015

Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreem...

01.06.2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored...

01.06.2015

Ultragenyx Initiates New Development Program Studying KRN23 for t...

01.05.2015

New Clinical Trial Will Evaluate Antibacterial Envelope in Cardia...

12.29.2014

Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cel...

12.23.2014

Mirati Therapeutics Doses First Patient in Expansion Cohorts of P...

12.18.2014

CardioDx Raises $35 Million in Equity Financing

12.18.2014

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collab...

12.15.2014

Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Z...

12.15.2014

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant H...

12.10.2014

IlluminOss Medical Caps off Flagship Year with Addition of New Pa...

11.25.2014

Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cou...

11.24.2014

Milestone Announces Positive Phase 1 Data for MSP-2017; Supports ...

11.18.2014

IlluminOss Medical Announces Conditional FDA Approval for Clinica...

11.13.2014

Chimerix’s Brincidofovir Selected for Use in Ebola Clinical...

11.08.2014

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ...

11.06.2014

Michael Grey Joins Mirati Therapeutics Board of Directors

10.30.2014

Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the T...

10.28.2014

Chimerix hammers out an emergency PhII Ebola study for antiviral

10.27.2014

Ultragenyx Granted Orphan Drug Designation for Triheptanoin for t...

10.20.2014

CardioDx Announces Results of Study Demonstrating the Benefits of...

09.25.2014

LabCorp Announces Agreement to Acquire LipoScience

09.22.2014

Medtronic Announces CE Mark and European Launch of TYRX(TM) Absor...

09.16.2014

Thrasos Announces Successful Formal Interim Analysis and Clinical...

09.15.2014

Rotation Medical Initiates Post-Market Clinical Study Of Rotator ...

09.15.2014

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 ...

09.08.2014

TESARO Announces Submission of Rolapitant New Drug Application (N...

08.11.2014

Mirati Therapeutics Receives Orphan Designation from U.S. Food &#...

08.05.2014

Ultragenyx Announces License of Intellectual Property for the Tre...

07.31.2014

New Data on Chimerix’s Brincidofovir Supports Safety and An...

07.30.2014

MedStar Union Memorial Hospital is First Hospital in Country to O...

07.14.2014

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (lipro...

07.07.2014

CardioDx Announces Aetna and Coventry Health Coverage for Corus® ...

07.01.2014

Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for P...

07.01.2014

Rotation Medical Completes $27.2 Million Series B Financing

06.24.2014

Venture Partner Mike Grey named EY Entrepreneur Of The Year San D...

06.24.2014

Ultragenyx Announces Results from Phase 1/2 Study of KRN23 in X-l...

06.17.2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Fo...

06.03.2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents ...

05.14.2014

Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extensi...

05.12.2014

Shire adds to rare disease portfolio with acquisition of Lumena P...

05.12.2014

TESARO Announces Successful Achievement of Primary and All Second...

05.09.2014

Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 ...

05.06.2014

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA o...

05.05.2014

New Study Results Further Reinforce that the Corus® CAD Test Help...

04.30.2014

Ultragenyx Announces Positive Data From Phase 2 Study of Sialic A...

04.23.2014

MUSC Foundation for Research Development welcomes Art Pappas to b...

04.17.2014

IlluminOss receives new patents for bone stabilization system

03.27.2014

Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Rec...

03.11.2014

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

03.11.2014

Ultragenyx Announces First Patient Enrolled in Phase 2 Study of T...

03.10.2014

Study Finds the Corus® CAD Gene Expression Blood Test Influenced ...

02.24.2014

Marina Biotech Announces $6 MM Convertible Preferred Stock Financ...

02.12.2014

Ultragenyx Announces Presentation of Data From a Single Patient T...

02.11.2014

Ultragenyx Announces Initiation of Phase 2 Study for Patients wi...

02.06.2014

Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board...

02.06.2014

IlluminOss Medical introduces bone stabilization system in Spain,...

02.05.2014

Ultragenyx Announces Closing of Initial Public Offering and Exerc...

01.30.2014

Ultragenyx Announces Pricing of Initial Public Offering

01.22.2014

LipoScience Announces Appointment of Howard Doran as President an...

01.08.2014

Pappas Ventures Promotes Scott Weiner to Partner

01.06.2014

Medtronic Announces Acquisition of TYRX, INC., Developer of Solut...

12.20.2013

Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Ex...

12.17.2013

Ultragenyx Investigational New Drug Application for Triheptanoin ...

12.10.2013

Pappas Ventures Names Franz B. Humer as Venture Partner and Senio...

12.04.2013

FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord N...

11.18.2013

Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug ...

11.12.2013

Envisia Therapeutics Debuts with $25 Million Series A Financing

11.05.2013

Inhibition of ASBT Improves Liver Function in an Animal Model of ...

10.29.2013

Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LU...

10.22.2013

CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Di...

10.10.2013

New Data Highlight Value of Corus® CAD in Reducing Unnecessary Ca...

10.06.2013

Ultragenyx Announces the Presentation of Data from a Single Dose ...

10.02.2013

Chimerix Announces Publication of Positive Phase 2 Results of Bri...

09.26.2013

Ultragenyx Announces Three Abstracts Accepted for Poster Presenta...

09.26.2013

Lumena Pharmaceuticals Receives Orphan Drug Designation from US F...

09.26.2013

Lumena Pharmaceuticals Launches Global Clinical Program to Evalua...

09.24.2013

Ultragenyx selected as 2013 Fierce 15 Company

09.16.2013

Ultragenyx Announces Positive Data from Retrospective Study of UX...

09.11.2013

Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results

09.09.2013

Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX00...

09.04.2013

LipoScience Announces New Data Supporting High-Density Lipoprotei...

09.03.2013

Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Deve...

08.27.2013

Syndax Pharmaceuticals Secures $26.6 Million Series B Financing f...

08.14.2013

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus S...

08.14.2013

Ultragenyx Receives Approval of Clinical Trial Application (CTA) ...

08.12.2013

TYRX Announces First U.S. Implantation of AIGISRx® R Fully Biores...

08.05.2013

Ultragenyx Initiates New Development Program Studying Triheptanoi...

07.31.2013

LipoScience Research Sheds Light On Novel Markers Via Nuclear Mag...

07.23.2013

TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Pati...

07.23.2013

TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Enve...

07.23.2013

Stem cell therapy for transplants developed by Athersys Inc. may ...

07.15.2013

Chimerix CEO: Public market is critical to financing biotech R�...

07.11.2013

Ultragenyx Gains Worldwide Rights for Triheptanoin (UX007)

07.09.2013

TYRX Receives FDA Clearance for Fully Resorbable AIGISRx® R Antib...

07.03.2013

Ultragenyx Announces a Positive Signal in Interim Data from Phase...

06.28.2013

Mirati Therapeutics and MethylGene Announce Completion of Plan of...

06.28.2013

TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) ...

06.26.2013

Zero Infections in High-Risk Cardiac Device Replacements Reported...

06.24.2013

Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study ...

06.19.2013

Repurposing a cholesterol drug candidate for cholestatic liver di...

05.21.2013

Liquidia Technologies Announces Extension of Collaboration with P...

05.21.2013

Scott will provide his perspective on the investment outlook for ...

05.15.2013

Art Pappas Elected to NVCA Board of Directors

05.15.2013

Ultragenyx Advances Clinical Development of UX003 for the Treatme...

05.10.2013

Independent Study Shows Significant Decline in Cardiac Device Inf...

05.02.2013

Nanotechnology firm Liquidia plans new ophthalmology company

05.01.2013

Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Se...

05.01.2013

Ultragenyx Press Release: Ultragenyx Appoints Eric Yuen, MD as Ch...

04.22.2013

Jayson Punwani will moderate a discussion on Impact Investing at ...

04.22.2013

Scott Weiner will moderate a discussion on the current IPO market...

04.15.2013

TyRx Press Release – TYRX® Announces First EverImplantation...

04.15.2013

TYRX® Announces First EverImplantation of AIGISRx® R Fully Resorb...

04.12.2013

Chimerix stock pops 34% after IPO at $14 per share

04.12.2013

Chimerix stock pops 34% after IPO at $14 per share

04.11.2013

Chimerix Announces Pricing of Initial Public Offering

04.11.2013

Chimerix Announces Pricing of Initial Public Offering

04.08.2013

Ultragenyx Initiates Novel Disease Monitoring Program for Heredi...

04.08.2013

Ultragenyx Initiates Novel Disease Monitoring Program for Heredi...

04.08.2013

UltraGenyx Press Release – Ultragenyx Initiates Novel Disea...

03.21.2013

Art Pappas will moderate the panel “Driving Innovation from...

03.20.2013

Art Pappas will join the panel, “The Research, Funding and ...

03.19.2013

Art Pappas joins a panel at the 2013 BIO International Convention...

03.12.2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

03.12.2013

Planning IPO, Chimerix says its antiviral makes FDA fast track

02.26.2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward...

02.26.2013

Man with a plan: Emil Kakkis aims to lure big-market drugs toward...

02.20.2013

Ernest Mario named Chairman of Chimerix

02.20.2013

Ernest Mario named Chairman of Chimerix

02.11.2013

Art Pappas will join the panel, “How the Other Half Lives: ...

01.30.2013

LipoScience Press Release – LipoScience Announces Closing o...

01.30.2013

LipoScience Announces Closing of Initial Public Offering

01.25.2013

LipoScience Press Release – LipoScience Prices Initial Publ...

01.10.2013

Ultragenyx Press Release – Ultragenyx Announces In-Licensin...

01.10.2013

Ultragenyx Announces In-Licensing of Clinical-Stage Product Trihe...

01.10.2013

LipoScience Sets IPO Term

01.09.2013

LIPOSCIENCE COLLABORATES WITH A LEADING ACADEMIC MEDICAL CENTER T...

12.20.2012

Ultragenyx Press Release – Raises $75 Million in Oversubscr...

12.20.2012

Ultragenyx Press Release – Ultragenyx Raises $75 Million in...

12.20.2012

Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing

11.16.2012

The Wistar Institute Welcomes Three New Board Members

11.16.2012

The Wistar Institute Welcomes Three New Board Members

11.12.2012

Chimerix Press Release – Chimerix Appoints Michelle Berrey ...

11.12.2012

Chimerix Appoints Michelle Berrey Chief Medical Officer

10.29.2012

Jayson Punwani will moderate a panel at the 2nd annual Kenan-Flag...

10.25.2012

Thrasos Press Release – Thrasos Secures $35 Million to Fund...

10.25.2012

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Prog...

10.04.2012

TyRx Press Release – TYRX(R) Receives Health Canada Approval

10.04.2012

TYRX(R) Receives Health Canada Approval

10.02.2012

TyRx Press Release – FierceMedicalDevices Names TYRX® as on...

10.02.2012

FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medica...

10.02.2012

CardioDx Press Release – CardioDx Honored as One of FierceM...

10.02.2012

CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most P...

10.02.2012

Two Pappas Ventures’ Portfolio companies make FierceMedical...

09.27.2012

IlluminOss Press Release – IlluminOss Medical Secures $28 M...

09.27.2012

IlluminOss Medical Secures $28 Million Series C Financing for Min...

09.20.2012

Mike Grey will join a panel to discuss the future of venture capi...

09.19.2012

Pappas-backed CoLucid gets FDA accord

09.19.2012

Pappas-backed CoLucid gets FDA accord

09.18.2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for ...

09.18.2012

CoLucid Pharmaceuticals Details Phase 3 Development Strategy for ...

09.14.2012

TyRx Press Release – TYRX(R) Receives New Product Innovatio...

09.14.2012

TYRX(R) Receives New Product Innovation Award

09.05.2012

LipoScience Press Release – LipoScience Receives FDA Cleara...

09.05.2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

09.05.2012

LipoScience Receives FDA Clearance for Vantera Clinical Analyzer

08.27.2012

CardioDx Press Release – CardioDx Completes $58 Million Equ...

08.27.2012

CardioDx Completes $58 Million Equity Financing

08.21.2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Respons...

08.21.2012

Over 50% of Hospital CFOs Plan to Adopt New Technology in Respons...

08.20.2012

TyRx Press Release – Over 50% of Hospital CFOs Plan to Adop...

08.20.2012

Art Pappas joins a Venture Capital Panel at Mid-Atlantic Bio on S...

08.14.2012

Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012...

08.08.2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

08.08.2012

CardioDx Wins Medicare OK of Molecular Test for Heart Disease

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

08.02.2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections...

07.31.2012

Scott Weiner will join a panel discussion around perspectives on ...

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.24.2012

Merck snags Chimerix antiviral HIV program in $168.5M deal

07.12.2012

Clinical Data Finds Strong Association Between HDL Particles and ...

07.12.2012

Clinical Data Finds Strong Association Between HDL Particles and ...

07.09.2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

07.09.2012

Pappas Ventures Names Pat Gage to Scientific Advisory Board

07.09.2012

Art Pappas makes TBJ “Triangle’s Most Influential Bus...

07.05.2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusi...

07.05.2012

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusi...

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.29.2012

Tesaro raises $81M in a rare IPO success story

06.25.2012

MethylGene announces encouraging data from Phase I tumor study

06.25.2012

MethylGene Announces Encouraging Data from Phase 1 Tumor Study

06.20.2012

Liquidia Announces Product Development Collaboration with GSK

06.20.2012

Liquidia Announces Product Development Collaboration with GlaxoSm...

06.20.2012

Liquidia Announces Product Development Collaboration with GlaxoSm...

06.20.2012

Liquidia Technologies signs lucrative deal with GSK

06.06.2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

06.06.2012

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

06.05.2012

CED Selects Officers and Board of Directors Members

05.23.2012

Mike Grey will join a discussion panel entitled “Are we Hea...

05.16.2012

Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Dir...

05.15.2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particl...

05.15.2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particl...

05.15.2012

Achillion gets FDA incentives for hepatitis C drug

05.15.2012

Achillion gets FDA Incentives for Hepatitis C Drug

05.14.2012

Scott will join a panel discussion focusing on raising US venture...

05.03.2012

Liquidia Founder Dr. Joseph DeSimone Elected into National Academ...

05.01.2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclu...

05.01.2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclu...

04.30.2012

CardioDx Honored as 2012 Gold Edison Award Winner

04.30.2012

CardioDx Honored as 2012 Gold Edison Award Winner

04.26.2012

LipoScience Receives 2012 Diagnostic Marketing Association Creati...

04.26.2012

LipoScience Receives 2012 Diagnostic Marketing Association Creati...

04.23.2012

Ultragenyx Relocates Company Headquarters to Support Operational ...

04.19.2012

Syndax Pharmaceuticals Inc. Appoints Arlene Morris as CEO

04.06.2012

Liquidia figuring out how to ‘unleash’ technology

04.06.2012

Orphan Diseases and the Future of BioPharma, the Focus of the 201...

04.06.2012

Syndax Pharmaceuticals Inc. Appoints Arthur M. Pappas to Board of...

04.03.2012

Liquidia CEO to Participate in Biotech Panel to Explore “How to C...

04.02.2012

Big business appeal of nanotechnology on display in Durham

04.02.2012

Big Business Appeal of Nanotechnology on Display in Durham

04.02.2012

What venture capitalists look for in personalized medicine invest...

03.28.2012

Turner will provide his perspective on adopting personalized medi...

03.27.2012

Athersys gets OK for German solid organ transplant clinical trial

03.27.2012

Athersys gets OK for German solid organ transplant clinical trial

03.26.2012

Tesaro promises rapid progress with cancer drugs in $86M IPO

03.26.2012

TESARO promises rapid progress with cancer drugs in $86M IPO

03.21.2012

Stem Cell Therapy Holds Promise for Strokes

03.21.2012

Stem Cell Therapy Holds Promise for Strokes

03.19.2012

Art will provide featured remarks to the Harvard Business School ...

03.19.2012

Art Pappas will participate on a panel to discuss exit strategies...

03.15.2012

Hagan Bill Could Speed Approval Process for Drugs

03.14.2012

Marina, ProNAi in cancer deal

03.14.2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Trea...

03.14.2012

Ultragenyx Granted Orphan Drug Designation for UX003 for the Trea...

03.09.2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study...

03.09.2012

Ultragenyx Announces the Completion of the Phase 1 Clinical Study...

03.06.2012

Eric Linsley offers perspective on personalized medicine’s develo...

03.05.2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Dir...

03.05.2012

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Dir...

02.29.2012

Art Pappas will moderate and lead a discussion entitled “Ar...

02.29.2012

BrainCells Inc. Announces the Successful Completion of the Single...

02.29.2012

BrainCells Inc. Announces the Successful Completion of the Single...

02.29.2012

Selventa Granted Patent for Discovery of Biomarker Profiles

02.28.2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatm...

02.28.2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatm...

02.21.2012

Eric Linsley will lead a discussion on “Partnering and Lice...

02.21.2012

Plexxikon receives European approval for Zelboraf

02.21.2012

Plexxikon receives European approval for Zelboraf

02.21.2012

Diabetes drug developer Lumena raises $2.5M; compound regulates b...

02.21.2012

Diabetes drug developer Lumena raises $2.5M; compound regulates b...

02.16.2012

First and Only Personalized Treatment for Deadliest Form of Skin ...

02.16.2012

First and Only Personalized Treatment for Deadliest Form of Skin ...

02.08.2012

Scott Weiner will present and sit on a panel at the IN3 Medical D...

02.06.2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 st...

02.06.2012

Transplant antiviral strong in phase 2; Chimerix plans phase 3 st...

02.02.2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinica...

02.01.2012

A Path Forward for the FDA

02.01.2012

A Path Forward for the FDA

02.01.2012

Athersys, Inc. Announces Positive Results of MultiStem(R) Clinica...

01.31.2012

Eric Linsley speaks on CED Life Science

01.27.2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2...

01.27.2012

Chimerix Announces Presentation of Final Data from CMX001 Phase 2...

01.23.2012

Selventa Granted Patent for Discovery of Biomarker Profiles

01.19.2012

Researchers uncover how new melanoma drug accelerates secondary s...

01.19.2012

Researchers uncover how new melanoma drug accelerates secondary s...

01.19.2012

PRINTed Nanoparticles Delivery Multiple Punches to Treat Prostate...

01.16.2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both ...

01.16.2012

Venture-Backed Biotech’s 2011 M&A Exits Outpaced Both ...

01.16.2012

Art Pappas speaks on life sciences innovation at Biotech Showcase...

01.09.2012

FDA New Drug Approvals in 2011 Outpace Recent Past

01.04.2012

Achillion hepatitis drug gets faster FDA review

01.04.2012

ACH-1625 Receives Fast Track Designation From the FDA for the Tre...

Upcoming Events.

Events Past Events

pappas_capitalFollow

Life Science Venture Capital Firm

Retweet on Twitter pappas_capital Retweeted

Amplyx Pharmaceuticals, Inc @AmplyxPharma·

We announced the closure of a Series C financing to advance clinical development of our novel product candidates for the treatment of life-threatening diseases affecting patients with compromised immune systems. Learn more: https://amplyx.com/amplyx-pharmaceuticals-adds-pfizer-and-adage-to-series-c-financing-bringing-total-to-over-90-million/

Reply on Twitter 1262769688217452544 Retweet on Twitter 12627696882174525441 Like on Twitter 12627696882174525447

pappas_capital @pappas_capital·

thrilled to unveil the latest fixture in our office @pappas_capital #happyhour #friyay

Reply on Twitter 1225933429868580865 Retweet on Twitter 1225933429868580865 Like on Twitter 12259334298685808655

pappas_capital @pappas_capital·

proud to share that two @pappas_capital portfolio companies - @mirumpharma and @curaseninc - have been featured amongst the "Top Life Sciences Startups to Watch in 2020". #biotechexcitement https://www.biospace.com/article/top-21-life-science-startups-to-watch-in-2020/ @biospace

Reply on Twitter 1214944123666522112 Retweet on Twitter 1214944123666522112 Like on Twitter 12149441236665221121